argenx SE/$ARGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Ticker
$ARGX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,599
ISIN
US04016X1019
Website
argenx SE Metrics
BasicAdvanced
$35B
35.43
$15.94
0.17
-
Price and volume
Market cap
$35B
Beta
0.17
52-week high
$658.93
52-week low
$510.06
Average daily volume
404K
Financial strength
Total debt to equity
0.71
Interest coverage (TTM)
79.79%
Profitability
EBITDA (TTM)
190.978
Gross margin (TTM)
49.59%
Net profit margin (TTM)
40.26%
Operating margin (TTM)
8.14%
Effective tax rate (TTM)
-194.04%
Revenue per employee (TTM)
$1,650,000
Management effectiveness
Valuation
Price to earnings (TTM)
35.426
Price to revenue (TTM)
12.875
Price to book
5.44
Price to tangible book (TTM)
5.62
Growth
Revenue change (TTM)
82.13%
Earnings per share change (TTM)
-382.53%
3-year revenue growth (CAGR)
90.69%
10-year revenue growth (CAGR)
81.32%
3-year earnings per share growth (CAGR)
11.40%
Bulls say / Bears say
argenx reported a significant profit of $169 million in Q1 2025, a substantial turnaround from a $62 million loss in the same period of 2024, indicating strong financial performance. (sec.gov)
The European Commission approved VYVGART subcutaneous injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in June 2025, expanding the market for this key product. (argenx.com)
argenx presented positive Phase 2 proof-of-concept results for efgartigimod in myositis and Sjögren’s disease at EULAR 2025, demonstrating potential for new indications. (argenx.com)
Despite strong product sales, argenx reported a net loss of $32.5 million for the six months ended June 30, 2024, indicating ongoing challenges in achieving consistent profitability. (sec.gov)
Research and development expenses increased to $450 million in the first half of 2024, up from $361 million in the same period of 2023, which may pressure future profitability. (sec.gov)
argenx's operating loss for Q2 2024 was $45 million, reflecting ongoing operational challenges despite revenue growth. (sec.gov)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
argenx SE News
AllArticlesVideos
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
Benzinga·3 weeks ago
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewsWire·1 month ago
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of $35B as of July 21, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 35.43 as of July 21, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of July 21, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.